



Press release 2022-10-27
Malmö, Sweden

aXichem obtains patent for phenylcapsaicin for use in the treatment of idiopathic pulmonary fibrosis

[aXichem AB \(publ\) \("aXichem"\)](#), that develops and markets analogue industrial compounds, announces that the company has received patent protection for the company's unique product, phenylcapsaicin, for use in the treatment of idiopathic pulmonary fibrosis (IPF).

"This is a strategically interesting patent for aXichem and it strengthens the patent portfolio in an excellent way in an area where the need for effective treatment is great. My hope is that in the future this patent will have commercial significance for the company and that phenylcapsaicin, with its unique properties, will be able to contribute to the more effective treatment of a severe disease", says Torsten Helsing, CEO of aXichem.

About IPF

Idiopathic pulmonary fibrosis (IPF) is a chronic disease characterized by progressive fibrosis (scarring) of the lungs, which means that symptoms worsen over time. The disease picture involves a persistent cough, recurrent lung infections and severe shortness of breath.

The background is largely unknown, but for example smoking, viral infections and stomach/intestine-related problems such as gastroesophageal reflux have possible causal links. There is currently no curative treatment for idiopathic pulmonary fibrosis. Treatment generally consists of rehabilitation programs and anti-inflammatory drugs.

The information was submitted, through the care of the contact person, for publication on 27 October, 2022, at 3 PM CEST.

Company contact: Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55.

Email: torsten.helsing@axichem.se

aXichem's business idea is to develop, patent and market analogue industrial compounds. The Company primarily works with phenylcapsaicin, a structural analogue of capsaicin with a wide range of applications, such as feed additives, marine anti-fouling products and certain pharmaceutical areas. aXichem's shares are listed on NASDAQ First North under AXIC A. Certified Adviser: Redeye. Read more about the company at www.axichem.se

aXichem AB • Södergatan 26 • 211 34 Malmö, Sweden • P: +46 46 780 06 73 • post@axichem.se